p53-based Cancer Therapy paper

2014-11-23

placemark:
ADENOVIRUS BASED THERAPY ONYX 015

p53-based Cancer Therapy
Cold Spring Harbor Perspectives in Biology
2010
A-Star Singapore and Karolinska Institutet Stockholm Sweden paper

-q
Gene therapy using
wild-type p53, delivered by adenovirus vectors, is now in widespread use in China

-q
Sophisticated animal models have
shown that activation of the p53 response in
even advanced tumors can be curative

-q
 p53 gene therapy, Gendicine, is approved
in China and its US counterpart, Advexin, has
shown activity in number of clinical trials.

-q
p53 based vac-
cines in cancer patients 
--me: what?  kind of like the telomerase vaccines. .  I don't know about this

-q
 Finally drug combi-
nations have been developed that can selectively
kill cancer cells that lack p53 function while
protecting normal cells (Sur et al. 2009)

-q
Jack Roth was the ?rst to attempt p53 gene
therapy in man. In 1996 he used direct injection
of a retroviral vector expressing human p53
under the control of an actin promoter to treat
non-small cell lung carcinoma (NSCLC)

-q
 although neutralizing antibodies can re-
duce infectivity, this is not as big a problem
as anticipated when measured in the clinic

-q
Using this initial approach many thousands of
patients have received p53-based gene therapies
in clinical trials mostly in the USA and in China

-q
Although some remarkable clinical cases have
been reported Advexin has not yet won approval
from the FDA and very recently the company
developing it was closed

-q
The
analysis of 2500 patients treated by Gendicine
has been published and the production facilities
and ?lings of the company are to a very high
international standard

azim58wiki: